APA

Stemmer S. M., Hardan I., Raz H., Adamou A. K., Inbar M., Gottfried M., Merrick Y., Cohen Y., Sulkes A., Ben-Baruch N., Pfeffer R. P., Brenner H. J. & Rizel S. (20030714). Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients. : Bone marrow transplantation.

Chicago

Stemmer S M, Hardan I, Raz H, Adamou A K, Inbar M, Gottfried M, Merrick Y, Cohen Y, Sulkes A, Ben-Baruch N, Pfeffer R P, Brenner H J and Rizel S. 20030714. Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients. : Bone marrow transplantation.

Harvard

Stemmer S. M., Hardan I., Raz H., Adamou A. K., Inbar M., Gottfried M., Merrick Y., Cohen Y., Sulkes A., Ben-Baruch N., Pfeffer R. P., Brenner H. J. and Rizel S. (20030714). Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients. : Bone marrow transplantation.

MLA

Stemmer S M, Hardan I, Raz H, Adamou A K, Inbar M, Gottfried M, Merrick Y, Cohen Y, Sulkes A, Ben-Baruch N, Pfeffer R P, Brenner H J and Rizel S. Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients. : Bone marrow transplantation. 20030714.